Community Sexual Health

Know your
status.
Own your
health.

ThirstAid is a discreet, shame-free resource for sexual health education, anonymous testing guidance, and the science your doctor hasn't caught up to yet — built by and for our community.

Why this exists
2.2M+
Reported STIs in the U.S. annually — the real number is significantly higher
CDC STI Surveillance 2024 (Provisional)
29%
of U.S. women have BV — rates climb significantly with multiple sexual partners, yet the male vector goes untreated
CDC NHANES; CDC STI Treatment Guidelines
63%
BV recurrence within 12 weeks when only the woman is treated — a trial stopped early because treating women alone is definitively inferior
NEJM DOI 10.1056/NEJMoa2405404
Sex workers are four times more likely to report a syphilis history vs. the general female population
ACOG Committee Opinion
Discreet TestingBV EducationPartner TreatmentNo JudgmentFree Clinic DirectoryPrEP + Doxy-PEPAnonymousCommunity HealthReal ScienceBuilt From Inside Discreet TestingBV EducationPartner TreatmentNo JudgmentFree Clinic DirectoryPrEP + Doxy-PEPAnonymousCommunity HealthReal ScienceBuilt From Inside

The system wasn't
built for everyone.

The STI crisis isn't a knowledge problem. It's an access problem — and the people carrying the most risk are systematically underresearched, underserved, and blamed for a cycle they didn't start alone.

More likely to report a syphilis history — sex workers vs. the general female population
ACOG Committee Opinion
28%
Gonorrhea or chlamydia prevalence among female sex workers, compared to under 0.5% in the general U.S. population
PMC8360669
+700%
Rise in congenital syphilis over the last decade. 12th consecutive annual increase in 2024.
CDC Provisional STI Surveillance, 2024
29%
of all U.S. women have bacterial vaginosis — most without symptoms, most not knowing why it keeps returning
CDC NHANES; NCBI NBK459216

The research gap nobody talks about

Most studies on STI transmission in sex work communities focus on street-level workers — a population with genuinely high-risk conditions that skews every statistic. High-end providers are largely absent from the literature. That absence doesn't mean the risk is absent. It means it's invisible.

What almost no published research examines is the client as the primary vector. A man who sees providers and also has a wife or committed partner at home is a transmission bridge — and he is almost never the one studied, tested, or treated. The providers in this community are largely health-conscious, regularly tested, and self-aware. Their clients often are not.

"BV-associated bacteria have been identified in high-concordance on the penile skin and inside the male urethra of partners of women with recurrent BV — yet until recently, no treatment protocol existed for men. They were the missing piece hiding in plain sight."

The vector is almost always the man

This is not a moral argument. It is a biological one. Men carry BV-associated bacteria asymptomatically — no discharge, no odor, no discomfort, no signal that anything is wrong. They have no clinical reason to seek treatment and no system that asks them to.

A client who sees multiple providers, visits a committed partner at home, and never gets tested is a hub node in a transmission network. The women in that network — providers and partners alike — treat, recover, and get reinfected. The man who is the common thread remains invisible to both the healthcare system and the research literature.

ThirstAid is built on the belief that closing this loop — getting clients tested, informed, and treated — is the highest-leverage public health intervention available to our community right now. The 2025 clinical evidence agrees.

The most common
infection no one
is treating correctly.

BV affects nearly 1 in 3 U.S. women. The recurrence rate is brutal. The science now shows why — and points directly at the untreated partner.

BV is not a hygiene problem. It is a bacterial imbalance most often triggered or reintroduced through sexual contact. Standard care has spent decades treating only the woman while the male reservoir goes untouched.
Multiple partners significantly increases risk. A national representative CDC study found increasing lifetime number of sex partners is one of the strongest independent predictors of BV — even after controlling for race, income, and other variables. CDC NHANES; Koumans et al., Sex Transm Dis · PubMed 17621244
Partner concurrency multiplies the risk further. Women whose partners had concurrent partners had BV prevalence of 46–55%, compared to 35% in women without partner concurrency. PMC5429208
50–70% recurrence within 6 months of standard antibiotic treatment — when only the woman is treated. This is the clinical norm. If it keeps coming back, this is exactly why. PMC7661182
NEJM StepUp Trial (2025): Treating male partners cut women's BV recurrence from 63% to 35% — a 45% relative reduction. The trial was stopped early because treating women alone was definitively inferior. Vodstrcil et al., NEJM · DOI 10.1056/NEJMoa2405404
ACOG updated its guidelines in October 2025 to formally recommend concurrent male partner treatment for recurrent BV — the first time in U.S. clinical history. Most providers don't know this yet. PMC12839515 · ACOG Clinical Practice Update, October 2025
BV dramatically increases susceptibility to HIV, gonorrhea, chlamydia, trichomoniasis, HPV, and HSV-2. It is not just a comfort issue — it is a gateway condition. CDC STI Treatment Guidelines, BV section

A note for partners

The research is clear: BV-associated bacteria are present on penile skin and in the male urethra without causing any symptoms. There's no discomfort, no signal, no clinical reason to suspect anything is wrong. But the bacteria are there, and they are part of the reinfection cycle. This isn't about blame — most men have no idea. The ACOG guidelines were updated because the trial data was impossible to argue with. Getting treated is a 7-day course, available online without a clinic visit, delivered discreetly to your door. It protects the people you care about and breaks a cycle that standard medicine ignored for decades. Partners who want treatment links can access them inside the member portal after signing up.

"Reinfection from partners is causing a lot of the BV recurrence women experience. This provides definitive evidence that BV is in fact an STI — and treating only the woman is no longer defensible."

Prof. Catriona Bradshaw, Monash University + Melbourne Sexual Health Centre · NEJM, 2025

Key Studies on BV and Sexual Transmission

StepUp Trial — First RCT showing combined oral + topical male partner treatment reduced BV recurrence from 63% to 35% in women. Trial stopped early. "Paradigm shift" per NEJM editorial. Vodstrcil et al. · NEJM · DOI 10.1056/NEJMoa2405404
ACOG Clinical Practice Update — First-ever U.S. clinical guideline recommending concurrent male partner treatment for recurrent BV. Formally recognizes BV's sexually transmissible nature. ACOG October 2025 · PMC12839515
CDC / NHANES National Prevalence Study — BV prevalence in U.S. women: 29.2% overall. Increasing number of lifetime sex partners is a significant independent predictor in multivariate analysis. Koumans et al. · Sex Transm Dis · PubMed 17621244
Partner Concurrency & BV — Women reporting definite partner concurrency had BV prevalence of 46–55% vs. 35% in those without. Independent risk factor in logistic regression. PMC5429208 · Sex Transm Infect
Penile Microbiota Concordance — BV-associated bacteria identified on penile skin and male urethra; strong concordance between women with recurrent BV and their male partners' penile microbiota. Muzny et al. · J Clin Microbiol · PMC10446871
Cost-Effectiveness of Male Partner Treatment — Male partner treatment becomes cost-saving at uptake of just 28% in high-income settings. Reduces downstream STIs, PID, and adverse pregnancy outcomes. Scientific Reports · Nature · 2026
BV as Overlooked STI — Review of 70+ years of evidence concludes BV-associated bacteria are sexually transmitted; community impact has been severely underestimated. George, Van Gerwen, Muzny · Expert Rev Anti Infect Ther · PubMed 41159595
Global Economic Burden — Annual cost of BV treatment estimated at $4.8 billion globally — not including the cost of associated complications, downstream STIs, or lost productivity. PMC7661182

You can prevent
the most serious
infections entirely.

Two medications exist right now that can prevent HIV and bacterial STIs before or after exposure. They are underused, underknown, and available online — often for less than the cost of one test.

Pre-Exposure Prophylaxis
PrEP
HIV Prevention
What it is: A daily prescription pill (Truvada or Descovy) that prevents HIV infection in HIV-negative individuals. When taken consistently, it is over 99% effective at preventing HIV from sex.

Who it's for: Anyone at ongoing risk for HIV — clients, providers, or partners. If you're sexually active and not on PrEP, the question is why not.

How to get it: Telehealth prescription, delivered to your door. No office visit, no awkward conversation. Available through member-linked services — sign up for access.
→ Service links available to members
Post-Exposure Prophylaxis (Bacterial)
Doxy-PEP
STI Prevention
What it is: Doxycycline 200mg taken within 72 hours of potential bacterial STI exposure. Reduces risk of chlamydia, gonorrhea, and syphilis by 65–80% in studies. CDC now endorses for high-risk individuals.

Who it's for: Anyone in our community with regular exposure risk. This is the intervention the CDC credits as one of the main drivers of recent modest STI decline — the exact population ThirstAid serves.

How to get it: Requires a prescription. In Washington state, generic doxycycline runs approximately $20–25/month with a discount card. Available via telehealth — member links inside.
→ Service links available to members

A note on Doxy-PEP and antibiotic resistance: Doxy-PEP is effective and widely recommended for high-risk individuals, but it is not appropriate for daily indefinite use by everyone. It requires a prescriber to evaluate your specific situation, existing medications, and risk profile. This is not a barrier — telehealth makes this a 15-minute conversation, or you can bring it up with your own doctor. The service links inside the member portal connect you directly to a licensed prescriber if you don't have one.

Is money or insurance
the barrier?
Here's where to go.

These clinics offer free or sliding-scale STI testing in the Seattle area. You pay what you can — or nothing at all. No insurance required.

King County Sexual Health Clinic
Harborview Medical Center. Full STI panel: HIV, syphilis, gonorrhea, chlamydia, hepatitis. Walk-in available. Sliding scale fees based on income — can be fully free. UW Medicine MyChart-compatible.
Free – Sliding Scale Walk-In
Sea Mar Community Health
90+ Washington state locations. Full STI panel. Free or sliding scale based on income. No immigration status requirements. Confidential. MyChart-compatible for results.
Free – Sliding Scale 90+ Locations
International Community Health (ICHS)
Multiple King County locations. Full panel. Sliding scale. Language access services available. Inclusive and confidential care environment.
Sliding Scale
WA State DOH Testing Locator
Find free or low-cost HIV, STI, and hepatitis testing near you statewide. The Washington State Department of Health maintains an up-to-date searchable directory of public health testing sites.
Statewide Free Options

Important on timing: Free and low-cost clinic results typically take 1 to 3 weeks to return depending on clinic capacity and the tests ordered. Some clinics are faster — call ahead to ask. If faster results matter to you, the next section is for you.

Is upfront cost,
fear of being seen,
or slow results the issue?

Free clinics are great — but they're not always the right fit. If what you need is fast, private, and on your terms, there are options for that too. Sign up for member access and we'll get you the lowest available pricing.

🏃
Results in 1–2 days
Walk into any major LabCorp or Quest location near you. Order online, pay privately. No insurance, no appointment, no waiting weeks. Results delivered to a secure online account — nothing mailed to your home.
📦
Mail-in kits
Order a kit online, collect your own sample at home, mail it back in a prepaid envelope. No clinic visit, no waiting rooms, no one to see you. Results in 3–5 days via secure portal. Available for all genders.
At-home rapid tests for women
Some at-home tests designed for women — including BV and certain STIs — give immediate results without sending anything to a lab. No waiting, no account needed, no digital footprint. Ask inside the member portal for current options.

Sign up free — unlock member pricing

Members get access to our curated list of the lowest-cost anonymous testing services available, plus a discount code for their first test. Some services ship kits directly to you. Signing up takes 30 seconds and is always free.

Join Free →

ThirstAid exists to educate, connect, and improve the health of our entire community — one test, one resource, one honest conversation at a time.

01
Built from inside
ThirstAid was built by someone who lives this, not someone who studies it. The people running this platform are members of the community they serve.
02
No shame, no judgment
Health is not a moral conversation. We give you the facts, the resources, and the tools — without opinions about how you live your life.
03
Give back
A portion of every dollar that flows through ThirstAid goes to community health funds, harm reduction programs, and international humanitarian aid.

The platform is coming.
Sign up now to be
first in line.

ThirstAid is building toward a full private health-sharing platform. What you're joining today is the foundation. Your support funds what's below.

📱
Verified Result Sharing
Upload your test results to the platform. Once verified by our team, generate a single one-time code to share your status — 24-hour expiry, view-once, no names attached. You stay in control entirely.
🤝
Sponsorships
Members who can afford to pay covering platform access for those who can't. A mutual aid model for health access built directly into the product.
🌐
Community Alerts
Lab-verified outbreak notifications sent to members when a confirmed case is reported. Manually reviewed. Non-identifying. Designed to inform, not expose.
🔓
Early Sign-Ups Stay Free
Joining now is free and always will be for early members. Phase 2 introduces a paid membership tier for the verified result-sharing platform — but everyone who signs up before launch locks in free access. Don't wait.

Signing up is free.
Always will be.